• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于室性心律失常的静脉用药的药代动力学和药效学

Pharmacokinetics and pharmacodynamics of intravenous agents for ventricular arrhythmias.

作者信息

Nolan P E

机构信息

Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson 85721-0207, USA.

出版信息

Pharmacotherapy. 1997 Mar-Apr;17(2 Pt 2):65S-75S; discussion 89S-91S.

PMID:9085342
Abstract

Although no antiarrhythmic agent has ideal pharmacokinetic and pharmacodynamic characteristics, it is useful to evaluate antiarrhythmic agents in terms this ideal profile. The most desirable characteristics of an intravenous antiarrhythmic agent for treating ventricular arrhythmias are outlined. The basic pharmacokinetic and pharmacodynamic properties of the most commonly used agents for this indication-including amiodarone, bretylium, lidocaine, procainamide, and quinidine-are also reviewed, in light of this profile.

摘要

尽管没有一种抗心律失常药物具有理想的药代动力学和药效学特性,但根据这一理想特性来评估抗心律失常药物是有用的。本文概述了用于治疗室性心律失常的静脉注射抗心律失常药物最理想的特性。鉴于此特性,还回顾了用于该适应症的最常用药物(包括胺碘酮、溴苄铵、利多卡因、普鲁卡因胺和奎尼丁)的基本药代动力学和药效学特性。

相似文献

1
Pharmacokinetics and pharmacodynamics of intravenous agents for ventricular arrhythmias.用于室性心律失常的静脉用药的药代动力学和药效学
Pharmacotherapy. 1997 Mar-Apr;17(2 Pt 2):65S-75S; discussion 89S-91S.
2
Ventricular arrhythmias and the use of antiarrhythmic drugs after cardiovascular surgery.
Am J Manag Care. 1998 Nov;4(11):1603-10; quiz 1611-12.
3
A screening method for antiarrhythmic agents in the rat.大鼠抗心律失常药物的筛选方法。
Br J Pharmacol. 1970 May;39(1):229P.
4
Advanced cardiac life support controversy: where do antiarrhythmic agents fit in?高级心脏生命支持争议:抗心律失常药物在其中扮演什么角色?
Pharmacotherapy. 1997 Mar-Apr;17(2 Pt 2):84S-88S; discussion 89S-91S.
5
An overview of antiarrhythmic drug management of electrical storm.电风暴的抗心律失常药物治疗概述
Can J Cardiol. 1996 Apr;12 Suppl B:3B-8B; discussion 27B-28B.
6
Intravenous amiodarone.静脉注射胺碘酮。
Med Lett Drugs Ther. 1995 Dec 8;37(963):114-5.
7
Parenteral antiarrhythmic drug therapy in ventricular tachycardia/ventricular fibrillation: evolving role of class III agents--focus on amiodarone.用于室性心动过速/心室颤动的肠外抗心律失常药物治疗:Ⅲ类药物不断演变的作用——聚焦胺碘酮
J Cardiovasc Electrophysiol. 1995 Oct;6(10 Pt 2):914-9. doi: 10.1111/j.1540-8167.1995.tb00367.x.
8
Hemodynamic effects of antiarrhythmic drugs.
Am J Cardiol. 1983 Sep 22;52(6):14C-23C. doi: 10.1016/0002-9149(83)90627-6.
9
Human organic cation transporter 3 mediates the transport of antiarrhythmic drugs.
Eur J Pharmacol. 2004 Sep 19;499(1-2):45-51. doi: 10.1016/j.ejphar.2004.07.098.
10
Ventricular arrhythmias: current concepts.
Compr Ther. 1984 Sep;10(9):32-6.

引用本文的文献

1
Molecular mechanism matters: Benefits of mechanistic computational models for drug development.分子机制至关重要:机制性计算模型在药物研发中的益处。
Pharmacol Res. 2015 Sep;99:149-54. doi: 10.1016/j.phrs.2015.06.002. Epub 2015 Jun 18.
2
Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).心力衰竭患者药物的临床药代动力学:更新(第 1 部分,静脉内给药的药物)。
Clin Pharmacokinet. 2013 Mar;52(3):169-85. doi: 10.1007/s40262-012-0029-2.